1 / 16

Hatch-Waxman Revisited

Hatch-Waxman Revisited. Allows patent owners to recover time spent in clinical trials and FDA regulatory review Specifically, pioneer companies are granted an extra half-day of patent life for every day spent in clinical trials and an extra day for every day spent in FDA review period

cirila
Télécharger la présentation

Hatch-Waxman Revisited

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hatch-Waxman Revisited • Allows patent owners to recover time spent in clinical trials and FDA regulatory review • Specifically, pioneer companies are granted an extra half-day of patent life for every day spent in clinical trials and an extra day for every day spent in FDA review period • There are 2 restrictions: • effective life of drug patent cannot exceed 14 years • total time restored cannot exceed 5 years

  2. However… • A patent term can only be extended once • Only one patent can be extended for a given regulatory review period • FDA authorization must be for first commercial use of active ingredient • Extensions are limited to what is covered by original FDA authorization

  3. Hatch-Waxman & Generics • Generic share of prescription market has grown from 19% (1984) to 53% (2003) • This act permits generic manufacturers to cite safety and efficacy data from pioneer FDA applications • This relieves the burden of clinical trials (as long as bioequivalence is demonstrated) • Generic manufacturers are permitted to initial clinical tests (to demonstrate bioequivalence) before pioneer patents expire

  4. Naming Drugs • Drugs have several types of names, each used for a different audience • Chemical and biological names are used to describe composition of small-molecule or biological drugs • Generic names are shared between branded and generic drugs to indicate common ingredients • Trade names of drugs are proprietary names used by different firms to brand their products

  5. Chemical & Biological Names • Chemical or biological names provide scientific descriptions of drug composition • Chemical name for ibuprofen is 2-[4-(2-methylpropyl)phenyl] propanoic acid • Biological name for Amgen’s Epogen is recombinant erythropoietin

  6. Generic Names • A generic name is created using specific nomenclature system and is used to identify generic versions of a branded drug • Generic name for Amgen’s Epogen is epoetin alfa • Ibuprofen is generic name for drugs marketed under Advil (Wyeth), Motrin (McNeil) and other trade names

  7. Generic Names Table 8.4 Selected generic drug naming conventions

  8. Trade Names • Trade names are used to uniquely brand an individual company’s version of the drug • A trade name must be approved by the FDA and cannot imply efficacy • Trade names are protected by trademark law, preventing generics from using them even after patent expires • This encourages pioneers to develop strong brand identity to expand market dominance past patent expiration

  9. Other Naming Issues • Despite restriction that trade names cannot imply efficacy, drug makers often select names with connotations aligned with intended use • Examples: Vick’s Dayquil and Nyquil • Abbreviations may be used when appropriate (EPO common for epoetin alfa) • Drugs in development are referred to by their method of action (ex. ACE inhibitor) or internal code name (ex. MEDI-493 for Medimmune’s Synagis drug)

  10. Recombinant DNA Advisory Committee (RAC) • Established October 7, 1974 by NIH in response to public concerns about safety of genetic manipulation • Main goal is to consider current state of knowledge and technology regarding recombinant DNA. Responsibilities include: • Review of human gene transfer trials • Assessment of ability of DNA recombinants to survive in nature • Potential for transfer of genetic material to other organisms

  11. RAC • Also considers hypothetical hazards and methods for monitoring and minimizing risks • Committee members include scientists and non-scientists (representing public) • Guidelines include description of facilities and practices intended to prevent unauthorized release or inadvertent exposure to GMOs or rDNA • Compliance is mandatory for those receiving funding from NIH

  12. US Department of Agriculture (USDA) • Regulates plant pests, plants, and veterinary biologics • Important to determine if plant is safe to grow outdoors • Several USDA agencies exist to regulate and monitor use of biotechnology in agriculture • Food Safety Inspection Service is responsible for monitoring safe use of engineered domestic livestock, poultry, and products derived from them

  13. USDA - APHIS • Animal and Plant Health Inspection Service(APHIS) is responsible for protecting agriculture from pests and diseases • It regulates movement, importation, and field testing of GMOs through permits and notification procedures • APHIS also has Veterinary Biologics and Biotechnology Regulatory Services divisions • Other agencies include Foreign Agriculture Service & Economic Research Service

  14. Environmental Protection Agency (EPA) • Regulates microbial and plant pesticides of chemical and biological origin, new uses of existing pesticides, and novel organisms that have industrial uses • BioPesticides and Pollution Prevention Division regulates distribution, sales, use, and testing of plants and microbes producing pesticidal substances

  15. EPA • EPA sets tolerance limits for substances used on and in food and feed • EPA also sets tolerances for residues of herbicides used • Toxic Substances Control Act Biotechnology Program regulates microbes intended for commercial use that contain or express new combinations of traits • GE plants and organisms must conform with standards set by state and federal marketing statutes

  16. Securities and Exchange Commission (SEC) • Mission is to protect investors, maintain fair, orderly, and efficient markets, and facilitate capital formation • SEC is responsible for ensuring that company public disclosures are accurate and complete • Challenge is that many biotech company disclosures are protected by FDA (not public information), so SEC usually does not usually have sufficient information • FDA has improved communications with SEC and began releasing carefully worded press releases to inform public of inconsistencies within a company

More Related